TKIs in CML and the holistic approach to treatment decisions video
Speaker: Professor Richard Clark
Richard Clark is Professor of Haematology at the University of Liverpool, UK. He studied medicine at Cambridge and Westminster Medical School, London, and, after his junior posts, co-established myeloid leukaemia research at Cardiff with Professor Allan Jacobs, as a research fellow and later Senior Lecturer. He moved to Liverpool in 1990 as Senior Lecturer and Consultant Haematologist and Director of the Regional Bone Marrow Transplant (BMT) programme at Royal Liverpool University Hospital.
Professor Clark’s research interests over the past 30 years have been in myeloid leukaemias, especially chronic myeloid leukaemia (CML). He is the chief or principal investigator for numerous trials in both acute leukaemia and myeloid malignancies and most recently the lead and chief investigator of one of the largest UK-wide study of discontinuation of TKIs in CML.
In this video, Richard discusses:
- Chromosomal abnormalities
- Prognostic markers
- Longer term clinical data for bosutinib
- His approach to changing treatments either due to efficacy or side effects
PP-BOS-GBR-0983. April 2020